Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.
about
Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategyA decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectivesTumour Heterogeneity: The Key Advantages of Single-Cell AnalysisMechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung AdenocarcinomaDrug resistance missense mutations in cancer are subject to evolutionary constraintsRational design of non-resistant targeted cancer therapiesEfficacy analysis of tyrosine kinase inhibitors on rare non-small cell lung cancer patients harboring complex EGFR mutationsErlotinib response in an NSCLC patient with a novel compound G719D+L861R mutation in EGFR.Correlation of EGFR expression, gene copy number and clinicopathological status in NSCLC.Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatmentHigh proportion of rare and compound epidermal growth factor receptor mutations in an Australian population of non-squamous non-small-cell lung cancer.Comparison of uncommon EGFR exon 21 L858R compound mutations with single mutation.Epidermal growth factor receptor gene mutation status and its association with clinical characteristics and tumor markers in non-small-cell lung cancer patients in Northwest ChinaAn Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2.Epidermal growth factor receptor exon 20 p.S768I mutation in non-small cell lung carcinoma: A case report combined with a review of the literature and investigation of clinical significanceCompound EGFR mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma.Kinase inhibitor-responsive genotypes in EGFR mutated lung adenocarcinomas: moving past common point mutations or indels into uncommon kinase domain duplications and rearrangements.Effectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer.Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network.Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations.Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment.Concomitant Presence of EGFR and ALK Fusion Gene Mutation in Adenocarcinoma of Lung: A Case Report and Review of the Literature.EGFR mutations in non-small cell lung cancer: an audit from West China Hospital.S768I Mutation in EGFR in Patients with Lung Cancer.Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer.Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis.Uncommon EGFR mutations in a cohort of Chinese NSCLC patients and outcomes of first-line EGFR-TKIs and platinum-based chemotherapy.Clinical mutational profiling of 1006 lung cancers by next generation sequencing.Evaluation of EGFR, KRAS and BRAF gene mutations in renal cell carcinoma.Twenty-One Novel EGFR Kinase Domain variants in Patients with Nonsmall Cell Lung Cancer.Molecular biological analysis in a patient with multiple lung adenocarcinomas.EGFR mutation status in Tunisian non-small-cell lung cancer patients evaluated by mutation-specific immunohistochemistry
P2860
Q26744284-216C0906-9DC5-4C1B-A201-9832809BE7EBQ26797297-71516B0D-6351-4939-8C8A-921B7A3BCB39Q28066914-5A837D64-4320-42A5-AD90-EB75AB6B0130Q28069900-D0347A0C-97A0-471D-A497-6E346D7EDCB5Q28537830-F8ADC76B-E637-4028-B31D-984820B86ADBQ33594692-FABC0761-DD8F-4454-8C6C-F6C4D8246FD9Q34055400-8EEA94B8-4077-485C-8AEA-D89BA25B8DC4Q34134464-81D9CA20-8EC7-4808-8314-749B940D4F4AQ34252140-6EE40F02-C0F3-4FF9-9A79-F642E3480EE5Q35227986-D1D83FF3-871D-4FF7-9386-1CE2A008D813Q35257336-053A00B7-32C4-4A13-8EF7-7C275D4265A3Q35541933-DE8E7807-025E-4BDD-BA6A-CF7B6A746F04Q35802647-BB886BBC-A6F7-4E9B-82E1-072C05C52C18Q35920986-581A5085-AE8E-48A2-8D25-98F875092DB7Q36503084-D0101953-BFE1-4200-A315-1F5645BF97EDQ36844350-FA21513C-7BD6-4929-9E5C-9C7D2A7158ECQ37060709-22680C47-8B50-40D2-8D59-BED742B389EBQ37344500-7F058301-9341-41DA-B8CF-C2251E613B11Q37404105-4E1E6F82-D56C-47A9-881F-AF6100F7E517Q37697306-7880FEA8-B3D2-495B-B853-ADF8D8920DCDQ39163315-C822327A-8556-4267-999C-12CE5D09DE38Q39259095-557496A6-F7F1-4EC5-B250-EB859FC42DF1Q39651867-813EB3A7-97DB-4BD6-B98B-F0D5BEE88937Q39745401-452DEA6C-A2CA-43AE-BDF4-1030E7CEFB7DQ47146662-AA4608A9-2706-4278-A873-F7FF540DDCF5Q47261717-C71741C1-D078-4734-B2AD-550D0963C47CQ49379624-53B21F76-B070-47A1-B43B-74ECA9445013Q49930825-CFFB67CF-85D6-422E-B04A-164418970DFEQ51763288-055E3A5B-6CAA-453C-BCC1-F668E5A23EC3Q55041728-E62D7413-F110-49CE-A527-E9D632444D0CQ55378668-765788B1-650B-45FA-AAFC-0D1504424637Q58793364-B8C726A8-713A-4F65-BE93-00FE70A7CA07
P2860
Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.
@ast
Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.
@en
type
label
Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.
@ast
Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.
@en
prefLabel
Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.
@ast
Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.
@en
P2093
P2860
P1476
Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors
@en
P2093
Alexandra S Bailey
Hannah M Canepa
Mark S Huberman
Michael A Goldstein
Norihiro Yamaguchi
Sohei Nakayama
Susumu Kobayashi
P2860
P356
10.1097/JTO.0B013E3182781E35
P577
2013-01-01T00:00:00Z